ArticleOpen forum infectious diseases2026
Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024-2025 Observational Case-series.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Modified Vaccinia Ankara-Bavarian Nordic vaccination (MVA-BN) prevents mpox, whether offered subcutaneously or intradermally. Intradermal administration has been implemented as a dose-sparing strategy, but evidence on durability of protection and long-term clinical impact is limited. We evaluated mpox severity over time in a limited number of mpox cases following primary intradermal MVA-BN vaccination. Methods: We conducted a retrospective case series of laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual health center in Stockholm, Sweden. Demographic and clinical data, vaccination history, and treatment outcomes were extracted from medical records. Disease severity was assessed using the validated Mpox Severity Score System. Results: Seventy-nine patients were included (median age, 40 years); 32 unvaccinated and 47 had prior vaccination with smallpox vaccine (n = 6), smallpox plus MVA-BN (n = 11), or MVA-BN only (n = 30). All MVA-BN doses were administered intradermally. Breakthrough infections occurred a median of 22 months after MVA-BN vaccination. Vaccinated individuals had significantly milder disease, with lower median severity score (5.0 vs 8.0; Conclusions: Dose-sparing intradermal MVA-BN vaccination is associated with sustained reduction in mpox severity for up to 3 years. Continued vaccination of high-risk populations is supported, while prospective studies are needed to clarify long-term protection and optimize vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.